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Abstract
Background:  As part of a program to develop a Dengue virus vaccine which avoids the
deleterious effects of antibody dependent enhancement (ADE) of infection mediated by antibodies
to Dengue virus structural proteins, we have begun to investigate the possibility of designing
Dengue vaccines based on non-structural proteins.
Results:  Dengue constructs which lack major structural proteins replicate intracellularly in tissue
culture. These replicons are capable of prolonged expression of Dengue virus non-structural
proteins for at least seven days in culture.
Conclusions:  Dengue virus genomes lacking major structural proteins can, like other flaviviruses,
replicate intracellularly and express virus non-structural proteins with minimal toxicity to host
cells. These findings pave the way for the development of dengue virus replicons as a form of live,
attenuated virus vaccine.
Background
The mosquito-borne flavivirus, Dengue, is estimated to
cause in each year 100 million cases of Dengue fever
(DF), 500,000 cases of Dengue Hemorrhagic fever
(DHF) and 25,000 deaths, with 2.5 billion people at risk
[1]. Although a successful vaccine against the prototypi-
cal flavivirus, yellow fever (YF) virus, has been in use
since the 1930s and vaccines to two other flaviviruses,
Japanese encephalitis (JE) virus and tick-borne en-
cephalitis (TBE) virus are currently available, there is as
yet no Dengue vaccine approved for use [2].
Dengue virus has a typical flavivirus genome structure,
as described in Figure 1A. The structural proteins, C, prM
(M) and E, are involved in packaging, export and subse-
quent entry. The non-structural proteins, NS1, NS2A,
NS2B, NS3, NS4A, NS4B and NS5 include an RNA-di-
rected RNA polymerase, and a protease function in-
volved in cleaving certain positions of the long viral
polyprotein which contains all the viral genes [3,4].
The four serotypes of Dengue virus ("1" through "4")
share approximately 60%–74% amino acid residue iden-
tity with one another in the E gene [5] and induce cross-
reacting antibodies [6]. However, neutralizing antibod-
ies to the structural proteins of one serotype of Dengue
typically not only fail to provide protection against other
serotypes, but appear to cause the enhanced replication
of virus seen in Dengue hemorrhagic fever, which is gen-
erally seen upon reinfection by Dengue virus of a differ-
ent serotype. This antibody-dependent enhancement of
infection (ADE), which is believed to be mediated by en-
hancement of viral uptake by macrophages [7] compli-
cates Dengue vaccine development, since an inadequate
or modified immunogen may contribute to disease, rath-
er than prevent infection [8].
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Figure 1
A. Diagram of Dengue virus genome and deletion mutations in this study. B. Sequences at the deletion points of mutants used
in this study.BMC Microbiology 2001, 1:18 http://www.biomedcentral.com/1471-2180/1/18
Two strategies suggest themselves for circumventing the
problems caused by cross reacting antibodies against the
major structural proteins, prM and E. One strategy is to
immunize with multiple strains of Dengue virus to elicit
high affinity, neutralizing antibodies against the multiple
Dengue serotypes. At least one vaccine to do this (using
dengue vaccine candidates DEN-1 PDK13, DEN-2
PDK53, DEN-3 PGMK 30/F3, and DEN-4 PDK48) has
been in clinical trials [9,10]. A second strategy is to in-
duce immunity only to viral proteins other than prM and
E. Several studies have shown that the nonstructural
glycoprotein NS1 can play an important role in protec-
tion against Dengue. Mice immunized with purified Den-
gue-2 NS1 protein injected intramuscularly and boosted
after 3 days and two weeks were protected from develop-
ing lethal Dengue encephalitis upon subsequent chal-
lenge with Dengue 2 virus. [11]. Similarly, mice
immunized with recombinant vaccinia virus expressing
authentic NS1 [12] were protected against the develop-
ment of Dengue-4 virus encephalitis when challenged by
intracerebral injection. Inoculation of mice with specific
combinations of MAbs directed against Dengue-2 NS1
[13] also protects against lethal virus encephalitis upon
intracerebral Dengue-2 challenge. Other nonstructural
proteins are also immunogenic and may participate in
eliciting protection [14].
Towards the goal of devising a "live" vaccine based on
only non-structural Dengue proteins, we have attempted
to construct Dengue virus genomes from which the pre-
M and E genes have been deleted. Upon introduction
into a host's cells, these sub-genomic fragments should
replicate intracellularly and support prolonged expres-
sion of Dengue non-structural proteins without produc-
ing the deleted structural proteins and without forming
infectious virions. Sub-genomic replicons of several pos-
itive-strand RNA animal viruses have been reported,
particularly yellow fever and Kunjin among the flavivi-
ruses. These replicons, when introduced into host cells,
replicate and make viral proteins for over 41 days [15],
but cannot form infectious virions because they lack crit-
ical structural proteins. Effectively delivered to host cells
in vivo, such replicons should efficiently induce immu-
nologic reactions against the expressed proteins remain-
ing in the sub-genomic construct. Here we describe the
successful construction of two Dengue virus sub-genom-
ic constructs which replicate in LLC-MK2 cells in tissue
culture when transfected in as full length RNA. We also
report that expression of Dengue virus proteins from at
least one of these replicons can be supported by transfec-
tion of a DNA-based expression vector containing the
replicon.
Results
Immunofluorescent analysis of cell cultures 48 hrs post
transfection demonstrates efficient expression of Den-
gue virus proteins from wild type Dengue virus as well as
from both the ∆ prM-E and ∆ C-prM-E mutants (see Fig-
ure 1 and Figure 2A,2B & 2C). By this time point, the wild
type virus has had a limited opportunity to be transmit-
ted in secondary rounds of infection. Interestingly, pairs
of fluorescent cells were often seen, suggesting cells con-
tinued to replicate after being successfully transfected by
replication competent Dengue replicons. This is particu-
larly evident in Figure 2B & 2C.
By 8 days post transfection, wild type Dengue virus ex-
pression is more widespread throughout the culture than
it was 48 hrs post transfection, presumably because it
was able to undergo multiple rounds of replication and
transmission (Figure 2D). Cell cultures transfected with
∆ prM-E (Figure 2E) or ∆ C-prM-E (Figure 2F) still have
cells efficiently expressing Dengue proteins at 8 days, but
they are more rare than they were at 48 hrs post transfec-
tion. This is consistent with the inability of these mutants
to make infectious virions and suggests that the viral
proteins remaining in the Dengue replicons may moder-
ately retard cell growth and replication. However, in the
experiments presented here, cells were trypsinized and
replated on day 7 post transfection, so they may not have
had sufficient time to recover and replicate prior to har-
vest for immunofluorescence on day 8.
No fluorescent cells were ever seen at either 48 hrs or 8
days post transfection with Dengue deletion mutant ∆ E,
from which most of the E gene has been deleted. Howev-
er, negative results are hard to interpret in this system.
The prolonged expression of Dengue virus proteins by
the ∆ prM-E and ∆ C-prM-E replicons presumably is de-
pendent on the ability of these sub-genomic fragments to
replicate. Consistent with this presumption, ∆ prM-E
RNA was seen to sequentially increase in cultures over at
least the first 48 hrs post transfection (Figure 3), whereas
no Dengue virus RNA was seen over this time period af-
ter transfection with ∆ E RNA. RNA from both of these
constructs is undetectable at 6 hrs post transfection, sug-
gesting that most of the transfecting RNA is rapidly de-
graded.
When the ∆ -prM-E replicon is placed under the control
of a cytomegalovirus (CMVB) promoter, it is still capable
of active Dengue virus protein expression when trans-
fected into cells in the form of plasmid DNA (see Figure
4).
Discussion
The expression of Dengue virus RNA and proteins in cul-
tures transfected with the ∆ -prM-E and ∆ C-prM-E mu-
tants is consistent with replication of the viral sub-BMC Microbiology 2001, 1:18 http://www.biomedcentral.com/1471-2180/1/18
Figure 2
Expression of Dengue virus as determined by immunofluorescent staining with mouse anti-Dengue virus-2. Cells were coun-
terstained with Evans Blue, but different filtration systems available on the different microscopes variably blocked visualization
of the background of cells fluorescing red. Transfection efficiencies were generally in the range of 0.01% to 1% and in the back-
ground of each photograph in this figure are numerous non-fluorescent cells, best visualized on an Apple Macintosh. In the
experiments here, cells were photographed variously with either 40X or 60X objectives. A, Dengue 2 wild type virus (48 hrs);
B, ∆ prM-E (48 hrs);C, ∆ C-prM-E (48 hrs); D, Dengue 2 wild type (8 days); E, ∆ prM-E (8 days); F, ∆ C-prM-E (8 days).BMC Microbiology 2001, 1:18 http://www.biomedcentral.com/1471-2180/1/18
genomes in these host cells. This is consistent with simi-
lar replicons constructed from Kunjin virus [15]. Most
encouraging, however, is the finding of viral protein ex-
pression at long time points (8 days) subsequent to
transfection with the ∆ prM-E and ∆ C-prM-E replicons in
the absence of selection. Previous experiments with oth-
er flavivirus replicons have demonstrated expression for
as long as 41 days post transfection [15], but these repli-
cons expressed neomycin and were grown under selec-
tive pressure. The longest, previously reported time for
pure replicon expression in the absence of selection was
just 72 hours [15]. We have not yet searched for contin-
ued expression beyond 8 days post transfection, but we
have no reason to believe that is not readily achievable.
In order for the Dengue replicons reported here to be of
immunologic value, they need to be expressible in a con-
venient form and (we anticipate) they need to produce
NS1 protein. Formally, the data presented here do not di-
rectly prove NS1 production, because the antisera used
detect multiple viral structural and nonstructural pro-
teins. Attempts to visulize Dengue replicon protein syn-
thesis by Western blotting were unsuccessful in our
hands (data not shown), presumably because of the com-
paratively low transfection efficiencies achieved. Howev-
er, the previously demonstrated dependence of Dengue
virus replication on NS1 production [16] and the fact that
Dengue virus RNA levels increase with time after trans-
fection in the cultures used here (implying active Dengue
RNA replication) together strongly imply the production
of significant quantities of NS1 protein by these repli-
cons. As for a suitable form of delivery, the ability of
pDNA-∆ prM-E to make high levels of Dengue proteins
after transfection into cells in the form of DNA suggests
the possibility of using DNA transfection to achieve im-
munization [17].
Conclusions
We have demonstrated the prolonged expression of Den-
gue virus proteins from sub-genomic Dengue RNA frag-
ments, lacking major structural genes, transfected into
tissue culture cells. This prolonged expression is associ-
ated with detectable increases in Dengue RNA in the
transfected tissue cultures, implying that the sub-ge-
nomic fragments are replicating, and implying the syn-
thesis of NS1 protein and other viral non-structural
proteins known to be required for viral genomic replica-
tion. The ability to express one of these sub-genomic
Dengue replicons from transfected DNA offers the possi-
bility of using DNA-based, Dengue replicon vaccines. Ex-
periments are currently in progress to develop other
delivery methods, including the development of packag-
ing cell lines.
Materials & methods
Culturing of Dengue virus
Dengue virus strains DEN1/WP and DEN2/NGC, kindly
provided by Dr. Lewis Markoff, [18,19] were passaged in
monkey LLC-MK2 cells at 37° C in a humidified incuba-
tor under 5% CO2, using Medium 199 plus 10% fetal bo-
vine serum (FBS) and 50 ug of Gentamicin per ml. The
cells were trypsinized a day before virus infection and
plated to reach approximately 80% confluence on the
day of infection. Infections were typically at an MOI of
0.01 PFU/cell in Medium 199 plus 2% FBS.
Figure 3
Dengue virus RNA in transfected cells as determined by RT-
PCR, normalized to total RNA: Lane 1, λ  Hind-Ill molecular
weight markers; Lanes 2–4, ∆ prM-E; 5–7, ∆ E; 2 & 5, 6 hrs; 3
& 6, 24 hrs; 4 & 7, 48 hrs.
Figure 4
Expression of Dengue virus proteins by DNA-∆ prM-E trans-
fected into cells in the form of plasmid DNA.BMC Microbiology 2001, 1:18 http://www.biomedcentral.com/1471-2180/1/18
In vitro mutagenesis
DNA fragments used for spanning the desired deletions
(see Figure 1) were synthesized by polymerase chain re-
action (PCR) from two short overlapping primers. For
the ACME replicon, the 5' primer was
5ATCATTATGCTGATTCCAACAGTGATGGCGTTCCAT
TTAACCACACGTAA CAGCACCTCACTGTCTGTG3. For
the  ∆ prME replicon, the 5' primer was
5ACAGCTGTCGCTCCTTCAATGACAATGCGTTGCATA
GGAATATCAAATA GAAGCACCTCACTGTCTGTG3. For
both mutants, the 3' PRIMER was
5ATACAGCGTCACGACTCCCACCAATACTAGTGACAC
AGACAGTGAGGTG CT3
PDNA-∆ prM-E was constructed by placing the ∆ prM-E
replicon RNA under the transcriptional control of a CMV
promoter and placing it upstream of a Hepatitis Delta Vi-
rus (HDV) self cleaving ribozyme.
Dengue-2 virus cDNA cloned in the yeast shuttle vector
pBR424, linearized by excision of a short Bam HI frag-
ment was transfected into competent [20] S. cerevisiae
YPH857 (kindly provided by Barry Falgout (CBER/
FDA), along with the appropriate PCR fragment span-
ning the desired deletion. Yeast colonies which grew on
tryptophan minus plates represented vectors which had
recircularized by homologous recombination with these
PCR fragments [20]. DNA from these colonies was trans-
formed into E. coli Stbl 2 cells (Life Technologies, Inc.) to
make sufficient quantities of Dengue recombinant, ge-
nomic-length DNAs for characterization and analysis.
Expression of virus & replicons in cells
The full length virus and replicon cDNA plasmids isolat-
ed from Stbl 2 cells were linearized with Sac I, purified by
Qiagen chromatography, and eluted by RNase-free water
in preparation for transcription. The transcription reac-
tion mixtures contained lug of linearized DNA; 0.5 mM
(each) ATP, CTP, and UTP; 0.1 mM GTP; 0.5 mM cap an-
alog (NEBL); 10 mM DTT; 40 U of RNasin (Promega);
30 U of SP6 RNA polymerase; and 1 ×  SP6 RNA polymer-
ase buffer (Promega) in a volume of 30 ul. The reaction
mixtures were incubated at 40°C for 2 hr. Aliquots (12.5
ul) of the reaction mixtures, containing full length viral
RNA, were used to transfect approximately 2 ×  106 mon-
key LLC-MK2 cells in phosphate-buffered saline (PBS)
by electroporation in a 0.4 cm gap electroporation cu-
vette. Each cuvette was pulsed at 200 V, 950 uF using a
BioRad Genepuls electroporator. The cells were then re-
suspended in growth medium and plated on the appro-
priate tissue culture dish. Plasmid DNA-∆ prM-E was
transfected into cells by electroporation using identical
conditions.
After electroporation, cells were either plated directly on
multiwell plates for harvest at short time periods (typi-
cally 48 hrs or less) or on tissue culture dishes for
trypsinization and seeding onto multiwell plates on the
day before final harvest for longer time periods (typically
8 days post transfection).
Immuno-histochemical methods
Cells growing on chamber slides were rinsed in room-
temperature PBS and then fixed in cold acetone for 10
min at -20°C. After being air dried, each chamber was
covered with 50 ul of a 1:50 dilution of DEN2-specific hy-
perimmune mouse ascitic fluid (HMAF, American Type
Culture Collection) in PBS plus 2% normal goat serum.
Samples were incubated at room temperature for 1 h in a
humidified atmosphere and then rinsed twice in PBS.
Samples were similarly incubated with a 1:100 dilution
of fluorescein isothiocyanate-labeld goat anti-mouse an-
tibodies (Life Technologies) and rinsed twice in PBS.
Cells in some experiments were counterstained with
0.02% Evans Blue.
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